Mechanistic Insights into Chemoselective Reduction of Engineered Cysteine Residues in Antibodies Using Computational Modeling and Rationally Designed Phosphines
- 8 April 2026
- journal article
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 148 (15) , 15463-15473
Abstract
Site-specific antibody-drug conjugates (ADCs) offer improved stability, efficacy, and toxicity relative to conventional ADCs. However, the chemoselective reduction of engineered cysteine residues employing phosphine-based reductants remains incompletely understood and difficult to generalize. Here, we integrate experimental screening with computational modeling to elucidate the mechanism of selective reduction and to derive principles for de novo design of chemoselective phosphine reductants. We propose a two-factor computational framework guided by phosphine accessibility to each disulfide site on the antibody surface and intrinsic reactivity, captured by the TS1 activation barrier, to explain selective versus nonselective behavior. This framework successfully rationalizes the activity of phosphine reductants toward engineered cysteine residues across two distinct engineered cysteine sites on the IgG1 backbone (S375C in the Fc and S168C in the Fab). Guided by these structure-function insights, we developed new reagents with improved chemoselectivity. Finally, by exploiting site- and reagent-dependent differences in accessibility and reactivity, we demonstrated the feasibility of a sequential strategy to prepare homogeneous dual-payload ADCs without complex linkers or additional antibody engineering. These findings provide broadly applicable guidance for phosphine selection and design to achieve chemoselective, site-specific conjugation.Keywords
This publication has 36 references indexed in Scilit:
- Dual-payload antibody–drug conjugates: Taking a dual shotEuropean Journal of Medicinal Chemistry, 2024
- Selective Reduction of Cysteine Mutant Antibodies for Site-Specific Antibody–Drug ConjugatesBioconjugate Chemistry, 2023
- The therapeutic window of antibody drug conjugates: A dogma in need of revisionCancer Cell, 2022
- A Platform for the Generation of Site-Specific Antibody–Drug Conjugates That Allows for Selective Reduction of Engineered CysteinesBioconjugate Chemistry, 2020
- Breaking a Couple: Disulfide Reducing AgentsChemBioChem, 2020
- Synthesis of a heterotrifunctional linker for the site-specific preparation of antibody-drug conjugates with two distinct warheadsBioorganic & Medicinal Chemistry Letters, 2018
- Orthogonal Cysteine Protection Enables Homogeneous Multi‐Drug Antibody–Drug ConjugatesAngewandte Chemie International Edition, 2016
- Location Matters: Site of Conjugation Modulates Stability and Pharmacokinetics of Antibody Drug ConjugatesChemistry & Biology, 2013
- Alternate States of Proteins Revealed by Detailed Energy Landscape MappingJournal of Molecular Biology, 2011
- Reduction of Aromatic Disulfides with Triphenylphosphine.Analytical Chemistry, 1964